Eversept Partners LP Invests $7.90 Million in Moderna, Inc. $MRNA

Eversept Partners LP bought a new position in Moderna, Inc. (NASDAQ:MRNA) in the 4th quarter, according to its most recent disclosure with the SEC. The firm bought 267,823 shares of the company’s stock, valued at approximately $7,898,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Lingotto Investment Management LLP increased its stake in shares of Moderna by 33.7% in the 4th quarter. Lingotto Investment Management LLP now owns 498,693 shares of the company’s stock worth $14,706,000 after acquiring an additional 125,598 shares in the last quarter. Douglas Lane & Associates LLC increased its stake in shares of Moderna by 14.4% in the 4th quarter. Douglas Lane & Associates LLC now owns 1,291,465 shares of the company’s stock worth $38,085,000 after acquiring an additional 163,031 shares in the last quarter. Nicollet Investment Management Inc. bought a new position in shares of Moderna in the 4th quarter worth about $897,000. Banco Santander S.A. increased its stake in shares of Moderna by 22.1% in the 3rd quarter. Banco Santander S.A. now owns 215,894 shares of the company’s stock worth $5,577,000 after acquiring an additional 39,056 shares in the last quarter. Finally, Sigma Planning Corp bought a new position in shares of Moderna in the 4th quarter worth about $907,000. 75.33% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: FDA briefing documents and staff reviews appear more constructive for Moderna’s flu vaccine, easing approval concerns ahead of the June 18 advisory committee meeting. MRNA Stock Jumps as FDA Briefing Docs Ease Flu Shot Approval Concerns
• Positive Sentiment: Moderna announced organizational changes, including a new chief commercial officer and expanded responsibilities for President Stephen Hoge, to prepare for multiple product launches in 2027 and 2028. Moderna Announces Organizational Changes to Prepare for Multiple Product Launches in 2027 and 2028
• Positive Sentiment: Moderna said preliminary FDA staff review data may support effectiveness of its flu vaccine in adults 65 and older, which could strengthen the case for approval. US FDA staff says data may support effectiveness of Moderna’s flu vaccine in older adults
• Positive Sentiment: Moderna will host an Investor Event “Science Day” on June 25, giving shareholders a closer look at its research platform and early development programs. Moderna to Host Investor Event – Science Day
• Neutral Sentiment: President Stephen Hoge sold 53,336 shares in a pre-arranged 10b5-1 plan, which is worth watching but was disclosed as part of an automatic trading arrangement rather than a sudden negative signal. Stephen Hoge insider trade
• Neutral Sentiment: Reuters reported Moderna is interested in investing in production facilities in Germany, potentially using plant closures by BioNTech as an opportunity; this is strategic, but still early-stage. Moderna interested in Germany production
• Negative Sentiment: FDA review coverage also noted some remaining questions around Moderna’s flu vaccine data, so approval is not yet assured. FDA review raises questions ahead of panel meeting on Moderna’s mRNA flu vaccine

Insider Activity

In other Moderna news, Director Abbas Hussain sold 5,682 shares of the firm’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $46.63, for a total transaction of $264,951.66. Following the completion of the sale, the director directly owned 12,066 shares in the company, valued at approximately $562,637.58. This trade represents a 32.01% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Thyme Klinger sold 3,471 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $50.00, for a total transaction of $173,550.00. Following the sale, the insider owned 67,468 shares of the company’s stock, valued at approximately $3,373,400. This represents a 4.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 125,088 shares of company stock valued at $6,193,713 in the last quarter. 10.80% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Royal Bank Of Canada increased their price target on shares of Moderna from $35.00 to $38.00 and gave the stock a “sector perform” rating in a research note on Monday, May 4th. Jefferies Financial Group set a $37.00 price target on shares of Moderna and gave the stock a “hold” rating in a research note on Tuesday, March 3rd. Barclays increased their price target on shares of Moderna from $25.00 to $48.00 and gave the stock an “equal weight” rating in a research note on Thursday, April 2nd. Morgan Stanley set a $33.00 price target on shares of Moderna in a research note on Friday, May 1st. Finally, UBS Group reiterated a “neutral” rating on shares of Moderna in a research note on Tuesday, May 26th. Two research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and five have given a Sell rating to the company. Based on data from MarketBeat.com, Moderna currently has a consensus rating of “Reduce” and a consensus target price of $36.60.

Moderna Stock Up 11.6%

NASDAQ:MRNA opened at $61.80 on Thursday. The firm has a market cap of $24.52 billion, a P/E ratio of -7.58 and a beta of 1.05. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.35 and a current ratio of 2.41. Moderna, Inc. has a fifty-two week low of $22.28 and a fifty-two week high of $62.30. The firm has a 50-day simple moving average of $50.05 and a two-hundred day simple moving average of $44.83.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Friday, May 1st. The company reported ($3.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.02) by ($0.38). The firm had revenue of $389.00 million for the quarter, compared to the consensus estimate of $236.37 million. Moderna had a negative net margin of 143.55% and a negative return on equity of 26.64%. The firm’s revenue for the quarter was up 260.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($2.52) earnings per share. Analysts predict that Moderna, Inc. will post -6.51 earnings per share for the current fiscal year.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.